

DID YOU KNOW

GENETIC TESTING

may help you find the **right medication** for your psoriasis



Participate in a clinical trial and help:

- Contribute to psoriasis research
- Improve the way your doctor selects medication
- Discover a personalized treatment option



New treatments for psoriasis are only discovered with research and clinical trials.

Your doctor is participating in a study to see if a genetic test can be used to help select the most appropriate medication for you, resulting in improved response to the medication.

What is the study?

This study is trying to determine if a genetic test (called Mind.Px) is helpful in guiding clinicians' selection of medications for psoriasis.

What is Mind.Px?


Mind.Px is a fast, simple, and minimally invasive genetic test that may help determine how an individual's genetic variations can influence their response to medication.

You might be eligible to participate in this study if:

- You are trying or have recently tried one of the biologic medications shown in this brochure under the section called "Medications included on the Mind.Px report," **and**
- Your symptoms of psoriasis are not improving despite at least 6 weeks on the treatment you are receiving, **and/or**
- You're unable to tolerate or not seeing any improvement with your current biologic medication and have discontinued it.


What determines if a biologic medication will work for you?

Selecting a medication that's right for someone is often a challenge due to each patient's individual response, which may be influenced by many genetic causes. Finding an appropriate medication can help avoid side effects, worsening symptoms, or the need to change medications. It may also save you the expense of costly biologic medicines that may not be effective for you.



"Genomics uses information about a person's genetic makeup, or genome, to choose the drugs and drug doses that are likely to work best for that particular person."

National Institutes of Health National
Human Genome Research Institute



Mind.Px™ Clinical Study: How it works

Participants are randomly assigned to one of two groups:

- A test group whose clinicians receive the Mind.Px™ results in about 2 weeks and can use them to select the medication used during the study
- A control group whose clinicians do not receive Mind.Px results before selecting a medication

All participants will be administered a Mind.Px dermal patch for the initial test results, which only takes a few minutes to complete. No blood draw is required. Your doctor will monitor your response to your psoriasis medication during subsequent, routine visits, and you will be asked questions about your psoriasis and overall health.

Even if you are in the control group, you will receive your Mind.Px results at the end of the study, which your doctor may still use to evaluate your medication.

Are there risks?

The Mind.Px test is performed using a simple, minimally invasive dermal patch, which is considered low risk. There is a small risk of allergic/inflammatory reactions at the test site for the dermal patch.

There is a risk of allergic/inflammatory reactions with any prescribed medications which your physician will monitor. This includes the psoriasis medication your doctor selects.



This simple, penny-sized, minimally invasive dermal patch collects genetic information in about 5 minutes.

About Mind.Px


Mind.Px is a genetic test that analyzes patient genomic information and integrates it with advanced bioinformatics and drug pharmacology. The genomic analysis of individualized genetic information provides actionable, data-driven decisions for you and your doctor.

Mind.Px was developed by Mindera Health and uses Artificial Intelligence to find matches between myriad biomarkers and treatment selection.



The Mind.Px report

The Mind.Px report will show your likely response to each of the most common biologic medication classes used in psoriasis medications. Your doctor may use these results to determine which of the biologic classes to choose your medication from.



TEST RESULTS

R

Responder

TNFα Inhibitor

Tumor Necrosis Factor Alpha Inhibitor

NR

Non-Responder

IL-17 Inhibitor

Interleukin 17 Inhibitor

R

Responder

IL-23 Inhibitor

Interleukin 23 Inhibitor

Biologic medication classes

TNFα	Biologic class that inhibits the activation of tumor necrosis factor alpha
IL-17	Biologic class that inhibits the activation of interleukin 17
IL-23	Biologic class that inhibits the activation of interleukin 23

Medications included on the Mind.Px report:

secukinumab	Cosentyx®
brodalumab	Siliq®
ixekizumab	Taltz®
tildrakizumab	Ilumya®
risankizumab	Skyrizi®
guselkumab	Tremfya®
certolizumab pegol	Cimzia®
adalimumab	Humira®



How do I join the study?

For more information about the study and to see if you qualify, visit us at www.match-mindpx.com or contact:

